These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31580188)

  • 1. Suppression of joint destruction with subcutaneous tocilizumab for Japanese patients with rheumatoid arthritis in clinical practice.
    Nakashima Y; Kondo M; Shono E; Ishinishi T; Tsukamoto H; Kuroda K; Maeyama A; Harada H; Maekawa M; Shimauchi T; Nagamine R; Jojima H; Yoshizawa S; Tsuru T; Otsuka T; Miyahara H; Suematsu E; Wada K; Yoshizawa S; Inoue Y; Fukuda T; Ikemura S; Haraguchi A
    Mod Rheumatol; 2020 Sep; 30(5):807-815. PubMed ID: 31580188
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and effectiveness of subcutaneous tocilizumab in patients with rheumatoid arthritis in a real-world clinical setting.
    Atsumi T; Fujio K; Yamaoka K; Tomobe M; Kuroyanagi K; Kameda H
    Mod Rheumatol; 2018 Sep; 28(5):780-788. PubMed ID: 29251032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period.
    Ogata A; Tanaka Y; Ishii T; Kaneko M; Miwa H; Ohsawa S;
    Mod Rheumatol; 2018 Jan; 28(1):76-84. PubMed ID: 28622048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study.
    Ishiguro N; Atsumi T; Harigai M; Mimori T; Nishimoto N; Sumida T; Takeuchi T; Tanaka Y; Nakasone A; Takagi N; Yamanaka H
    Mod Rheumatol; 2017 Mar; 27(2):217-226. PubMed ID: 27414105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
    Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T
    Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study.
    Ogata A; Tanaka Y; Ishii T; Kaneko M; Miwa H; Ohsawa S; Yamakawa R;
    Mod Rheumatol; 2019 Sep; 29(5):767-774. PubMed ID: 30299202
    [No Abstract]   [Full Text] [Related]  

  • 7. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY).
    Dougados M; Kissel K; Sheeran T; Tak PP; Conaghan PG; Mola EM; Schett G; Amital H; Navarro-Sarabia F; Hou A; Bernasconi C; Huizinga TW
    Ann Rheum Dis; 2013 Jan; 72(1):43-50. PubMed ID: 22562983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study).
    Kaneko Y; Kato M; Tanaka Y; Inoo M; Kobayashi-Haraoka H; Amano K; Miyata M; Murakawa Y; Yasuoka H; Hirata S; Tanaka E; Miyasaka N; Yamanaka H; Yamamoto K; Takeuchi T;
    Ann Rheum Dis; 2018 Sep; 77(9):1268-1275. PubMed ID: 29853455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis.
    Iwamoto N; Fukui S; Umeda M; Nishino A; Nakashima Y; Suzuki T; Horai Y; Nonaka F; Okada A; Koga T; Kawashiri SY; Fujikawa K; Aramaki T; Ichinose K; Hirai Y; Tamai M; Nakamura H; Terada K; Nakashima M; Mizokami A; Origuchi T; Eguchi K; Ueki Y; Kawakami A
    Mod Rheumatol; 2016 Sep; 26(5):662-6. PubMed ID: 26708444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.
    Burmester GR; Rigby WF; van Vollenhoven RF; Kay J; Rubbert-Roth A; Blanco R; Kadva A; Dimonaco S
    Ann Rheum Dis; 2017 Jul; 76(7):1279-1284. PubMed ID: 28389552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of six-week extended dosing interval with tocilizumab therapy in a prospective cohort as remission maintenance in patients with rheumatoid arthritis.
    Kikuchi J; Kondo T; Shibata A; Sakai R; Okada Y; Chino K; Okuyama A; Kurasawa T; Takei H; Amano K
    Mod Rheumatol; 2018 May; 28(3):444-451. PubMed ID: 28849709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and structural remission rates increased annually and radiographic progression was continuously inhibited during a 3-year administration of tocilizumab in patients with rheumatoid arthritis: A multi-center, prospective cohort study by the Michinoku Tocilizumab Study Group.
    Hirabayashi Y; Munakata Y; Miyata M; Urata Y; Saito K; Okuno H; Yoshida M; Kodera T; Watanabe R; Miyamoto S; Ishii T; Nakazawa S; Takemori H; Ando T; Kanno T; Komagamine M; Kato I; Takahashi Y; Komatsuda A; Endo K; Murai C; Takakubo Y; Miura T; Sato Y; Ichikawa K; Konta T; Chiba N; Muryoi T; Kobayashi H; Fujii H; Sekiguchi Y; Hatakeyama A; Ogura K; Sakuraba H; Asano T; Kanazawa H; Suzuki E; Takasaki S; Asakura K; Sugisaki K; Suzuki Y; Takagi M; Nakayama T; Watanabe H; Miura K; Mori Y;
    Mod Rheumatol; 2016 Nov; 26(6):828-835. PubMed ID: 26934116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction.
    Smolen JS; Avila JC; Aletaha D
    Ann Rheum Dis; 2012 May; 71(5):687-93. PubMed ID: 22121130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
    Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
    Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial.
    Sanmarti R; Veale DJ; Martin-Mola E; Escudero-Contreras A; González C; Ercole L; Alonso R; Fonseca JE;
    Arthritis Rheumatol; 2019 Oct; 71(10):1616-1625. PubMed ID: 31087542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study).
    Kaneko Y; Atsumi T; Tanaka Y; Inoo M; Kobayashi-Haraoka H; Amano K; Miyata M; Murakawa Y; Yasuoka H; Hirata S; Nagasawa H; Tanaka E; Miyasaka N; Yamanaka H; Yamamoto K; Takeuchi T
    Ann Rheum Dis; 2016 Nov; 75(11):1917-1923. PubMed ID: 26733110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tocilizumab can efficiently prevent bone destruction in patients with recent-onset rheumatoid arthritis.
    Hirabayashi Y
    Mod Rheumatol; 2021 Sep; 31(5):966-971. PubMed ID: 33274666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous Tocilizumab Is Effective for Treatment of Elderly-Onset Rheumatoid Arthritis.
    Kondo N; Fujisawa J; Endo N
    Tohoku J Exp Med; 2020 May; 251(1):9-18. PubMed ID: 32404541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].
    Avdeeva AS; Aleksandrova EN; Novikov AA; Cherkasova MV; Panasyuk EY; Nasonov EL
    Ter Arkh; 2013; 85(5):24-9. PubMed ID: 23819335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retention of tocilizumab with and without methotrexate during maintenance therapy for rheumatoid arthritis: the ACTRA-RI cohort study.
    Mori S; Yoshitama T; Abe Y; Hidaka T; Hirakata N; Aoyagi K; Ueki Y
    Rheumatology (Oxford); 2019 Jul; 58(7):1274-1284. PubMed ID: 30793749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.